Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.125 CAD | 0.00% | +8.70% | +92.31% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chris Moreau
CEO | Chief Executive Officer | 59 | 18-02-28 |
James Kinley
DFI | Director of Finance/CFO | 46 | 21-11-30 |
Chief Operating Officer | 41 | 21-02-28 | |
Ahmad Khalil
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Harry Bloomfield
CHM | Chairman | 79 | 21-09-07 |
Chris Moreau
CEO | Chief Executive Officer | 59 | 18-02-28 |
Mark Williams
BRD | Director/Board Member | 52 | 21-09-21 |
James Kinley
DFI | Director of Finance/CFO | 46 | 21-11-30 |
Raj Attariwala
BRD | Director/Board Member | 55 | 15-10-25 |
Howard Gutman
BRD | Director/Board Member | - | 22-02-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 21,940,779 | 17,393,981 ( 79.28 %) | 0 | 79.28 % |
Company contact information
Algernon Pharmaceuticals, Inc.
601 West Broadway Street Suite 400
V5Z 4C2, Vancouver
+604-398-4175
http://www.algernonpharmaceuticals.comSector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+92.31% | 1.93M | |
+16.61% | 121B | |
+17.75% | 110B | |
+17.23% | 25.98B | |
-24.11% | 19.27B | |
-18.56% | 15.99B | |
-18.47% | 15.66B | |
-47.75% | 14.5B | |
+57.35% | 14.47B | |
+5.62% | 13.91B |
- Stock Market
- Equities
- AGN Stock
- Company Algernon Pharmaceuticals Inc.